Figures computed from official regulatory filings — .
Analysttarget 7.97 USD (+110%) · consensus 4.75/5 · 7 buy · 1 hold · 0 sell
Ownershipinsiders 1.47% · institutions 57.25% · short 9.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for MANNKIND CORP only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
159 buys215 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Binder Steven B.track record | Sell | $128.5K | SEC |
| Binder Steven B.track record | Sell | $127.9K | SEC |
| Binder Steven B.track record | Sell | $158.5K | SEC |
| Castagna Michaeltrack record | Other | $261.7K | SEC |
| Thomson David | Other | $67K | SEC |
| Binder Steven B.track record | Other | $19K | SEC |
| Binder Steven B.track record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tross Stuart Atrack record | Other | $33.8K | SEC |
| Prentiss Christopher B | Other | $47.3K | SEC |
| Binder Steven B.track record | Sell | $213.1K | SEC |
| Castagna Michaeltrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tross Stuart Atrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Singh Sanjay R | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Binder Steven B.track record | Other | $64.2K | SEC |
| Thomson David | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Prentiss Christopher B | Other | $43.7K | SEC |
| Castagna Michaeltrack record | Other | $788.6K | SEC |
| Thomson David | Sell | $97.6K | SEC |
| Singh Sanjay R | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Binder Steven B.track record | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Thomson David | Other | $72.6K | SEC |
| Thomson David | Other | $211.2K | SEC |
| Singh Sanjay R | Other | $90.2K | SEC |
| Thomson David | Other | $51.8K | SEC |
| Singh Sanjay R | Other | $22K | SEC |